The deal in 4 points
USD 29 billion in cash and stock spent.
25% premium over the last closing price.
USD 15.3 billion of pro-forma combined sales in 2014.
Would be the biggest health care deal year to date, ahead of AbbVie-Pharmacyclics (USD 21bn) and Pfizer-Hospira (USD 16.7bn).
